The Massachusetts-based biotech company led by CEO Stéphane Bancel went from relative obscurity to the Wall Street spotlight when its mRNA-based COVID-19 vaccine, developed with scientists from the U.S. National Institute of Allergy and Infectious Diseases, became the first in the U.S. to start human testing last March. The vaccine’s December 2020 greenlight by the U.S. Food and Drug Administration—and its subsequent worldwide distribution—vindicates the company’s focus on using mRNA genetic material to teach the human body to fight off COVID-19. Millions have received the shot, and Moderna is ramping up production to meet continued worldwide demand.
More Must-Reads from TIME
- Cybersecurity Experts Are Sounding the Alarm on DOGE
- Meet the 2025 Women of the Year
- The Harsh Truth About Disability Inclusion
- Why Do More Young Adults Have Cancer?
- Colman Domingo Leads With Radical Love
- How to Get Better at Doing Things Alone
- Michelle Zauner Stares Down the Darkness
